JOP20190025A1 - طرق وتركيبة لتوقع نشاط إنزاستورين - Google Patents

طرق وتركيبة لتوقع نشاط إنزاستورين

Info

Publication number
JOP20190025A1
JOP20190025A1 JOP/2019/0025A JOP20190025A JOP20190025A1 JO P20190025 A1 JOP20190025 A1 JO P20190025A1 JO P20190025 A JOP20190025 A JO P20190025A JO P20190025 A1 JOP20190025 A1 JO P20190025A1
Authority
JO
Jordan
Prior art keywords
enzastaurin
prediction
activity
composition
methods
Prior art date
Application number
JOP/2019/0025A
Other languages
Arabic (ar)
English (en)
Inventor
Hong Sun
Wen Luo
Original Assignee
Denovo Biopharma Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Denovo Biopharma Llc filed Critical Denovo Biopharma Llc
Publication of JOP20190025A1 publication Critical patent/JOP20190025A1/ar

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/106Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/136Screening for pharmacological compounds
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/156Polymorphic or mutational markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Hospice & Palliative Care (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medical Treatment And Welfare Office Work (AREA)
JOP/2019/0025A 2016-09-01 2017-06-16 طرق وتركيبة لتوقع نشاط إنزاستورين JOP20190025A1 (ar)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662382734P 2016-09-01 2016-09-01
US201662414601P 2016-10-28 2016-10-28

Publications (1)

Publication Number Publication Date
JOP20190025A1 true JOP20190025A1 (ar) 2019-02-19

Family

ID=59923555

Family Applications (1)

Application Number Title Priority Date Filing Date
JOP/2019/0025A JOP20190025A1 (ar) 2016-09-01 2017-06-16 طرق وتركيبة لتوقع نشاط إنزاستورين

Country Status (15)

Country Link
US (2) US11421280B2 (enExample)
EP (1) EP3507384B1 (enExample)
JP (3) JP7197915B2 (enExample)
KR (1) KR20190046935A (enExample)
CN (1) CN109952383B (enExample)
AU (1) AU2017318669B2 (enExample)
BR (1) BR112019003951A2 (enExample)
CA (1) CA3035386A1 (enExample)
JO (1) JOP20190025A1 (enExample)
MX (1) MX2019002377A (enExample)
PH (1) PH12019500422A1 (enExample)
RU (1) RU2019109011A (enExample)
SG (2) SG10201912134TA (enExample)
TW (2) TW202313973A (enExample)
WO (1) WO2018045240A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20190025A1 (ar) 2016-09-01 2019-02-19 Denovo Biopharma Llc طرق وتركيبة لتوقع نشاط إنزاستورين
CN110496223B (zh) * 2018-05-17 2021-09-10 复旦大学附属肿瘤医院 一种治疗非霍奇金氏淋巴瘤的药物组合物
CN112512527A (zh) * 2018-09-12 2021-03-16 杭州索元生物医药股份有限公司 恩扎妥林和btk抑制剂的组合及其用途
CN111549033B (zh) * 2020-06-11 2021-02-12 南京市江宁医院 慢病毒感染人表皮角质细胞株及其构建方法和应用
US11227690B1 (en) * 2020-09-14 2022-01-18 Opendna Ltd. Machine learning prediction of therapy response
EP4376022A4 (en) * 2021-07-23 2025-07-16 Univ Kaohsiung Medical CLINICAL THERAPEUTIC DRUG PREDICTION AND RECOMMENDATION SYSTEM AND METHOD FOR EVALUATING THE EFFICACY OF A SECOND-GENERATION HORMONAL DRUG IN THE TREATMENT OF PROSTATE CANCER
US20230131677A1 (en) * 2021-10-21 2023-04-27 Toyota Research Institute, Inc. Systems and methods for predicting the effect of an intervention via machine learning
CN118339312A (zh) * 2021-11-23 2024-07-12 索元生物医药(美国)有限公司 用于评估多核苷酸递送和癌疗法之功效的组合物和方法
US12474842B2 (en) * 2021-12-13 2025-11-18 Google Llc Optimizing data placement based on data temperature and lifetime prediction

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2236702T3 (es) 1993-12-23 2005-07-16 Eli Lilly And Company Inhibidores de la proteina quinasa c.
WO2002014500A2 (en) 2000-08-16 2002-02-21 Chiron Corporation Human genes and gene expression products
US20040072217A1 (en) 2002-06-17 2004-04-15 Affymetrix, Inc. Methods of analysis of linkage disequilibrium
CA2393720C (en) 2002-07-12 2010-09-14 Eli Lilly And Company Crystalline 2,5-dione-3-(1-methyl-1h-indol-3-yl)-4-[1-(pyridin-2-ylmethyl)piperidin-4-yl]-1h-indol-3-yl]-1h-pyrrole mono-hydrochloride
WO2007145992A2 (en) 2006-06-05 2007-12-21 Perlegen Sciences, Inc. Genetic basis of treatment response in depression patients
WO2012106267A1 (en) 2011-01-31 2012-08-09 Wen Luo Method for discovering pharmacogenomic biomarkers
CN103649386B (zh) * 2011-06-08 2015-12-23 索元生物医药(杭州)有限公司 预测类视黄醇x受体调节剂活性的方法和组合物
JOP20190025A1 (ar) 2016-09-01 2019-02-19 Denovo Biopharma Llc طرق وتركيبة لتوقع نشاط إنزاستورين

Also Published As

Publication number Publication date
PH12019500422A1 (en) 2019-05-27
US20190233902A1 (en) 2019-08-01
US11421280B2 (en) 2022-08-23
AU2017318669A1 (en) 2019-03-07
AU2017318669B2 (en) 2023-04-20
TW202313973A (zh) 2023-04-01
JP2022173308A (ja) 2022-11-18
RU2019109011A (ru) 2020-10-05
CA3035386A1 (en) 2018-03-08
CN109952383A (zh) 2019-06-28
SG11201901762WA (en) 2019-03-28
EP3507384A1 (en) 2019-07-10
KR20190046935A (ko) 2019-05-07
JP7197915B2 (ja) 2022-12-28
TW201812125A (zh) 2018-04-01
CN109952383B (zh) 2024-01-05
BR112019003951A2 (pt) 2019-06-25
MX2019002377A (es) 2019-09-05
US20230074781A1 (en) 2023-03-09
TWI771317B (zh) 2022-07-21
RU2019109011A3 (enExample) 2021-01-22
EP3507384B1 (en) 2023-08-30
WO2018045240A1 (en) 2018-03-08
JP2020188816A (ja) 2020-11-26
JP2019528705A (ja) 2019-10-17
SG10201912134TA (en) 2020-02-27

Similar Documents

Publication Publication Date Title
PH12019500422A1 (en) Methods and composition for the prediction of the activity of enzastaurin
SG195191A1 (en) Methods and compositions of predicting activity of retinoid x receptor modulator
PH12017502153A1 (en) Diagnostic methods for t cell therapy
CL2019002427A1 (es) Inhibición de smarca2 para el tratamiento de cáncer.
MY203971A (en) Anti-lag-3 antibodies and compositions
EA201890725A1 (ru) Агонисты фарнезоидного х-рецептора и их применение
MX2018012492A (es) Métodos para monitorear y tratar el cáncer.
BR112017007975A2 (pt) composições e métodos para o tratamento de disfunção das glândulas meibomianas
MX2017016134A (es) Aril dihidro-2h-benzo[b][1,4]oxazina sulfonamida y compuestos relacionados para uso como agonistas de rory y el tratamiento de enfermedad.
EA201791874A1 (ru) Фторированные ингибиторы лизилоксидазоподобного фермента-2 и их применение
EA201890891A1 (ru) Биомаркеры, связанные с заболеваниями, опосредованными интерлейкином-33 (ил-33), и их применение
EA201890394A1 (ru) КОМПОЗИЦИИ НА ОСНОВЕ iRNA ДЛЯ ТРАНСТИРЕТИНА (TTR) И СПОСОБЫ ИХ ПРИМЕНЕНИЯ ДЛЯ ЛЕЧЕНИЯ ИЛИ ПРЕДУПРЕЖДЕНИЯ АССОЦИИРОВАННЫХ С TTR ЗАБОЛЕВАНИЙ
EA201692477A1 (ru) Композиции и способы применения для лечения метаболических расстройств
EA201692177A1 (ru) Соединения и композиции в качестве агонистов toll-подобного рецептора 7
PE20180260A1 (es) Metodos y kits para tratar la depresion
PH12021551455A1 (en) Jak1 pathway inhibitors for the treatment of gastrointestinal disease
MX2018012493A (es) Métodos para controlar y tratar el cáncer.
MX2016014306A (es) Marcadores para terapia con lipoproteinas de alta densidad (hdl).
BR112015019873A2 (pt) inibidores macrocíclicos da lrrk2 cinase
BR112017007704A2 (pt) derivados de pirazolopirimidina como inibidores de nik
BR112017007715A2 (pt) derivados de tienopirimidina como inibidores de nik
CA2939931C (en) METHODS AND COMPOSITIONS FOR TREATING DISEASES ASSOCIATED WITH SIGLEC8
MA40364A (fr) Polythérapie pour le traitement du cancer
CO2020008863A2 (es) Biomarcadores de tolerancia inmunitaria inducida por metotrexato
WO2016030334A3 (en) Methods, agents and compositions for treatment of inflammatory conditions